Long-acting synthetic luteinising hormone-releasing hormone agonists have become the mainstay for androgen-deprivation therapy, because they avoid the physical and psychological discomfort associated with orchidectomy and lack the potential cardiotoxicity associated with estrogens such as diethylstilbestrol. Currently available luteinising hormone-releasing hormone agonist analogues include leuprolide, goserelin, triptorelin, degarelix and buserelin were administered as either intramuscular or subcutaneous depot injections on a 1, 2, 3 or 6 months basis. Histrelin acetate is the first long-acting luteinising hormone-releasing hormone agonist available as a once-yearly subcutaneous implant.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Prostate artery embolization as an effective treatment for clinically significant prostate cancer‑related hemorrhage: A case report.
Exp Ther Med
February 2025
Department of Urology, Konstantopouleio-Patision General Hospital of Nea Ionia, 14233 Nea Ionia, Greece.
A 79-year old Caucasian male with metastatic hormone refractory prostate cancer and bilateral nephrostomy was admitted to the emergency department due to 4-day bloody urethral discharge, weakness and dizziness. The patient was treated with the luteinizing hormone-releasing hormone-antagonist and abiraterone acetate plus prednisone, dabigatran 150 mg bid (for atrial fibrillation and coronary heart disease) and 5-aminosalicylic acid for the management of mild ulcerative colitis. Imaging revealed bladder overdistention and blood analysis low levels of hematocrit (HCT) and hemoglobin (HGB) (HCT, 22%; HGB, 7.
View Article and Find Full Text PDFLuteinizing hormone-releasing hormone receptor agonists and antagonists in prostate cancer: effects on long-term survival and combined therapy with next-generation hormonal agents.
Cancer Biol Med
December 2024
Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China.
Prostate cancer is a leading cause of cancer-related death in men worldwide. Luteinizing hormone-releasing hormone receptor (LHRH-R) agonists and antagonists are known to achieve castration-level testosterone suppression; however, long-term data comparing the survival benefits of these therapies are insufficient to inform treatment decisions. Furthermore, the advent of next-generation hormonal agents (NHAs), such as abiraterone and enzalutamide, have shifted the paradigm of managing prostate cancer.
View Article and Find Full Text PDFThe Effect of Androgen Deprivation Therapy on the Cardiovascular System in Advanced Prostate Cancer.
Medicina (Kaunas)
October 2024
Department of Urology, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA.
Androgen deprivation therapy (ADT) is a mainstay treatment for metastatic prostate cancer, improving progression-free survival. ADT suppresses the production of testosterone and reduces circulating levels of the hormone. Luteinizing hormone-releasing hormone (LH-RH) agonists are the most commonly used ADT modality.
View Article and Find Full Text PDFEfficacy and safety of neoadjuvant chemohormonal therapy for high-risk prostate cancer treated with robot-assisted laparoscopic radical prostatectomy: a propensity score-matched analysis (the MSUG94 group).
Int Urol Nephrol
November 2024
Department of Urology, Gifu University Graduate School of Medicine, 1-1 Yanagito, Gifu, 501-1194, Japan.
Article Synopsis
- - The study aimed to compare the effectiveness and safety of neoadjuvant chemohormonal therapy (NCHT) versus radical prostatectomy (RP) alone in patients with high-risk prostate cancer undergoing robot-assisted surgery.
- - Data from 1,023 patients were analyzed, with results showing that those who received NCHT had a lower rate of biochemical recurrence (15.8% vs. 29.5%) and better pathology outcomes compared to the RP-only group.
- - The findings indicate that NCHT could be a beneficial pre-surgery treatment for high-risk prostate cancer, improving outcomes without significant safety concerns, although some adverse events were noted.
Effects of luteinizing hormone-releasing hormone analog and pimozide on the release of luteinizing hormone and ovulation in artificially matured Japanese eel Anguilla japonica.
Comp Biochem Physiol A Mol Integr Physiol
October 2023
Fisheries Technology Institute Minamiizu Field Station, Japan Fisheries Research and Education Agency, 183-2 Irouzaki, Minamiizu, Kamo, Shizuoka 415-0156, Japan. Electronic address:
Pituitary gonadotropins, follicle-stimulating hormone (Fsh) and luteinizing hormone (Lh), control oogenesis in all vertebrates. In particular, Lh plays a key role in stimulating the final oocyte maturation and subsequent ovulation. The biosynthesis and secretion of Lh are regulated by several neurohormones, including gonadotropin-releasing hormone (GnRH) and dopamine.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!